Court Will Examine Antitrust Implications Of Abbott Formulation Change
This article was originally published in The Pink Sheet Daily
Judge denies Abbott’s consolidated motion for dismissal in Tricor case.
You may also be interested in...
Company expects the lipid-lowering agent to eventually reach $1 bil. in revenue, almost double the U.S. sales level in 2003. Abbott points to "four strong formulation patents" on the fenofibrate tablet formulation which, it believes, will help keep generics at bay.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency